デュラグルチド（遺伝子組換え）

デュラグルチド（遺伝子組換え） 化学特性,用途語,生産方法

• 説明

  Dulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes. 

• brand name

  Dulaglutide is marketed by Eli Lilly as Trulicity.

• 作用機序

  The dulaglutide mechanism of action involves activation of the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in b cells. Thus, it increases intracellular cyclic AMP in these cells, leading to a glucose-dependent release of insulin. Dulaglutide also reduces secretion of glucagon and slows gastric emptying.

• Mode of action

  The mechanism of action of dulaglutide is as a Glucagon-like Peptide-1 (GLP-1) Agonist. Structurally, dulaglutide is made by replacing Ala with Gly at position 8, Glu with Gly at position 22, and Arg with Gly at position 36 on the GLP-1 (7-37) chain, with an average biological half-life of up to 90h.

デュラグルチド（遺伝子組換え） 生産企業

Global(152)Suppliers

923950-08-7, デュラグルチド（遺伝子組換え） キーワード